Orion Signs a License and Research Agreement with Alligator to Develop Bispecific Antibody for the Treatment of Cancer
Shots:
- Alligator to receive up front & research support payments. If Orion exercises its options to continue the development and commercialization of the product then Alligator will be further eligible to receive $548.41M as development- approval- and sales milestone for all three product candidates along with royalties
- The focus of the collaboration is to discover three novel bispecific Abs directed towards immuno-oncology targets- selected by Orion
- Following the collaboration- Alligator will use its phage display libraries and RUBY bispecific platform to develop immuno-oncology product candidates
| Ref: Alligator Bioscience | Image: Alligator Bioscience
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com